Neutrophil-to-lymphocyte ratio predicts early acute cellular rejection in living donor liver transplantation

Boram Lee¹, YoungRok Choi², Jai Young Cho¹, Yoo-Seok Yoon¹, Ho-Seong Han¹

¹Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
²Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

INTRODUCTION

Allograft rejection is regarded as one of the severe complications following liver transplantation (LT). Acute cellular rejection (ACR) after LT has decreased with the development of immunosuppressants, but it still affects 15%–25% of recipients [1,2]. Among those, approximately 5%–10% of recipients who had ACR can progress to severe chronic rejection [3,4]. Therefore, early diagnosis and proper treatment are essential for improving graft survival as well as patient prognosis [5,6].

In transplant recipients, liver biopsy is the gold standard for the diagnosis of acute rejection [7,8]. However, many studies have pointed out that it is invasive and its overall complications rate is 5%–7.1% [9,10]. The complications include minor complications like localized pain and mild transient hypotension to severe pain and major bleeding [11]. For these reasons, some centers do not perform a routine protocol liver biopsy without definite evidence of graft dysfunction. However, there are no definite guidelines for selecting patients for liver biopsy [12].

Purpose: The aim of this study was to evaluate the predictive value of neutrophil-to-lymphocyte ratio (NLR) in acute cellular rejection (ACR) after living donor liver transplantation (LDLT).

Methods: All consecutive patients who underwent ABO-compatible (ABOc) LDLT from September 2014 to December 2017 were retrospectively reviewed. NLR was calculated on 3 occasions; (1) 4 weeks prior to liver transplantation (LT), (2) the day of LT, and (3) the day before liver biopsy.

Results: Among 66 patients who underwent ABOc LDLT, ACR was identified in 15 patients (22.7%) on protocol liver biopsy performed routinely on the postoperative day 7. There was no significant difference in NLR at 4 weeks prior to LT and the day of LT between no-ACR and ACR group (2.98 ± 1.92 vs. 2.54 ± 1.15, P = 0.433; 17.9 ± 8.31 vs. 20.5 ± 13.4, P = 0.393). However, NLR was significantly lower in ACR group compared to non-ACR group just prior to liver biopsy (5.82 ± 3.42 vs. 18.4 ± 17.2, P = 0.035). NLR tends to decrease 3.5 days before the onset of ACR. The area under the receiver operating characteristic curve for optimal cut-off value of NLR was 6.49, with sensitivity and specificity of 80.4% and 73.3% respectively.

Conclusion: NLR has a potential as a noninvasive predictor of early ACR in ABOc LDLT.

Key Words: Liver transplantation, Lymphocytes, Neutrophils, Rejection
Noninvasive diagnostic tools, such as serum/urine biomarkers, cytological analysis, and imaging modalities were developed to avoid the complications of liver biopsy and safely predict ACR [13-18]. However, those methods were available only at laboratory level, were not reproducible and not freely available on the market.

The neutrophil-to-lymphocyte ratio (NLR) has been considered as a strong predictor of inflammation and poor prognosis in a variety of conditions such as cancer and transplantation [19,20]. ACR is the result of a complex series of interactions involving coordination between both the innate and adaptive immune system with T cells central to this process. Once recipient T cells become activated, they undergo clonal expansion, differentiation [20]. It is known that lymphocytes ultimately infiltrate the graft and circulate in the peripheral blood.

We hypothesize that the value of NLR changes in response to ACR after LT. This study aimed to evaluate the predictive value of NLR in ACR after living donor LT (LDLT).

METHODS

Patients

This study was a retrospective study using prospectively collected data from the electronic medical records of Seoul National University Bundang Hospital. Patients who underwent ABO-compatible (ABOc) LDLT between September 2014 to December 2017 were included. All recipients received modified right liver grafts from living donors. The following factors were excluded as they had the potential to influence the NLR after LT; (1) antibody-mediated rejection, (2) acute infection at biopsy, (3) systemic inflammatory response syndrome or sepsis at biopsy, and (4) additional administration of high-dose steroids over the routine protocol. The median follow-up of the study cohort was 55 months. This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital in Seongnam, Korea, an academic hospital affiliated with Seoul National University College of Medicine (No. B-1901-516-109). Written informed consent from patients was waived due to the retrospective nature of this study.

Protocol liver biopsy and acute cellular rejection grading

The measurement of resistive index (RI) by Doppler ultrasonography was performed in all patients on days 1, 2, and 3. Protocol liver biopsies and CT scans were performed routinely on postoperative day 7 to check the status of the liver graft and post-LT vasculature as well as abdominal complications. The following indications were considered for liver biopsy after discharge: (1) worsening of liver function or elevation in enzymes, (2) an abnormal increase in liver enzymes after the initial decrease, (3) unexpected abnormality of liver enzymes following a treated event, and (4) follow-up to a prior biopsy.

The histologic findings were graded according to the Banff schema. For statistical analysis, the rejection activity index (RAI) score was subsequently grouped as follows: RAI score < 2, no rejection; RAI = 2, indeterminate rejection; RAI score = 3–4, mild rejection; RAI score = 5–6, moderate rejection; and RAI score > 6, severe rejection [21]. The definition of ACR used in this study was more than 3 scores of RAI.

Immunosuppression protocol and treatment of ACR

When performing ABOc LDLT, basiliximab (Simulect, Novartis, Montreal, QC, Canada) was administered as the induction therapy, 20 mg on the day of surgery and the same dose on a postoperative day 4. The triple maintenance regimen for immunosuppression consisted of tacrolimus (target level: 8–12 ng/mL for 6 months, 6–8 ng/mL between 6 and 12 months post-LT), mycophenolate mofetil (500 mg twice per day), and steroids (methylprednisolone: 1,000 mg tapering to 20 mg/day). The first-line treatment of ACR was pulsed high-dose corticosteroids combined with increased serum levels of tacrolimus with the other immunosuppressant.

Neutrophil-to-lymphocyte ratio

The value of NLR was calculated as the percentage of neutrophils divided by the percentage of lymphocytes in the peripheral blood count. NLR was obtained on 3 occasions; (1) 4 weeks prior to LT, (2) the day of LT (NLR was calculated at postoperative day), and (3) 4 weeks prior to LT. The median follow-up of the study cohort was 55 months. This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital in Seongnam, Korea, an academic hospital affiliated with Seoul National University College of Medicine (No. B-1901-516-109). Written informed consent from patients was waived due to the retrospective nature of this study.

Statistical analysis

All statistical analyses were performed using IBM SPSS Statistics ver. 22.0 (IBM Corp., Armonk, NY, USA). Patient demographics were expressed as median (range). The Mann-Whitney U-test was used for comparisons between the ABOc LDLTs. P < 0.05 was considered statistically significant. The optimal cut-off values for low NLR with sensitivity and specificity were evaluated using the receiver operating characteristic (ROC) curve analysis.

RESULTS

Patients’ demographics and outcomes

Among 66 patients who underwent ABOc LDLT, ACR was identified in 15 patients (22.7%). The demographics of recipients in both the no-ACR and ACR groups are summarized in Table 1.
There was no significant difference in age, sex, underlying liver
disease, and blood type between both groups. The proportion
of patients with hepatocellular carcinoma was similar in both
groups (52.9% vs. 40.0%, P = 0.558). The model for end-stage
liver disease score (17.5 ± 0.57 vs. 15.7 ± 8.19, P = 0.158), total
bilirubin (6.36 ± 9.40 mg/dL vs. 6.66 ± 10.6 mg/dL, P = 0.134),
serum creatinine (1.18 ± 0.96 mg/dL vs. 0.76 ± 0.21 mg/dL, P =
0.707), and PT (international normalized ratio; 1.72 ± 0.57
vs. 1.70 ± 0.62, P = 0.370) were not significantly different in both
groups. The mean graft-to-recipient body weight ratio (1.11 ± 0.26
vs. 1.19 ± 0.31, P = 0.668) and the mean operation time (574.3
± 222.3 minutes vs. 456.6 ± 127.3 minutes, P = 0.039) were not
statistically different. The estimated blood loss was significantly
lower in the ACR groups compared to the non-ACR group (2,369.3
± 1,627.7 mL vs. 5,695.7 ± 12,077.7 mL, P = 0.007). The number
of patients who received transfusion were significantly higher
in the non-ACR group than the ACR group (packed red blood
cells, P = 0.039; fresh frozen plasma, P = 0.023; and platelet,
P = 0.025). The mean cold ischemic time (68.0 ± 26.2 minutes
vs. 77.6 ± 23.3 minutes, P = 0.187), the mean warm ischemic
time (46.9 ± 9.27 minutes vs. 49.4 ± 12.7 minutes, P = 0.187),
and the hospital stay (25.9 ± 21.7 days vs. 20.2 ± 11.2 days, P =
0.278) were not significantly different in both groups.

The interrelationship between neutrophil-to-
lymphocyte ratio and acute cellular rejection
Table 2 shows the relationship between NLR and ACR. In this
study, 15 patients (22.7%) developed histologically-confirmed

| Variable                  | No ACR (n = 51) | ACR (n = 15) | P-value |
|---------------------------|-----------------|--------------|---------|
| Preoperative condition    |                 |              |         |
| Age (yr)                  | 53.1 ± 9.53     | 47.6 ± 11.6  | 0.595   |
| Male                      | 35 (68.6)       | 8 (53.3)     | 0.358   |
| Female                    | 16 (31.4)       | 7 (46.7)     |         |
| Underlying liver disease  |                 |              |         |
| HBV                       | 32 (62.7)       | 7 (46.7)     | 0.131   |
| HCV                       | 8 (15.7)        | 2 (13.3)     |         |
| Alcoholic liver disease   | 5 (9.8)         | 0            |         |
| Autoimmune hepatitis      | 1 (2.0)         | 1 (6.7)      |         |
| Others                    | 5 (9.8)         | 5 (33.3)     |         |
| Hepatocellular carcinoma  |                 |              | 0.558   |
| Yes                       | 27 (52.9)       | 6 (40.0)     |         |
| No                        | 24 (47.1)       | 9 (60.0)     |         |
| Blood type                |                 |              | 0.138   |
| A+                        | 26 (51.1)       | 3 (20.0)     |         |
| B+                        | 14 (27.5)       | 5 (33.3)     |         |
| AB+                       | 4 (7.8)         | 2 (13.3)     |         |
| O+                        | 7 (13.7)        | 5 (33.3)     |         |
| MELD score                |                 |              |         |
| 17.5 ± 0.57               | 15.7 ± 8.19     | 0.158        |
| Total bilirubin (mg/dL)   | 6.36 ± 9.40     | 6.66 ± 10.6  | 0.134   |
| Creatinine (mg/dL)        | 1.18 ± 0.96     | 0.76 ± 0.21  | 0.707   |
| PT (INR)                  | 1.72 ± 0.57     | 1.70 ± 0.62  | 0.370   |
| Perioperative factor      |                 |              |         |
| GRWR (%)                  | 1.11 ± 0.26     | 1.19 ± 0.31  | 0.668   |
| Operation time (min)      | 574.3 ± 222.3   | 456.6 ± 127.3| 0.668   |
| Estimated blood loss (mL) | 5,695.7 ± 11,207.7 | 2,369.3 ± 1,627.7 | 0.007   |
| Transfusion (unit)        |                 |              |         |
| RBC                       | 11.3 ± 15.3     | 4.40 ± 4.85  | 0.039   |
| FFP                       | 11.2 ± 18.6     | 3.01 ± 4.62  | 0.023   |
| Platelet                  | 7.01 ± 13.7     | 1.86 ± 5.42  | 0.025   |
| Cold ischemic time (min)  | 68.0 ± 26.2     | 77.6 ± 23.3  | 0.187   |
| Warm ischemic time (min)  | 46.9 ± 9.27     | 49.4 ± 12.7  | 0.691   |
| Hospital stay duration (day)| 25.9 ± 21.7   | 20.2 ± 11.2  | 0.278   |

Values are presented as mean ± standard deviation or number (%).
ACR, acute cellular rejection; MELD, model for end-stage liver disease; INR, international normalized ratio; GRWR, graft-to-recipient
body weight ratio; FFP, fresh frozen plasma.
ACR at the routine protocol liver biopsy on a postoperative day 7. These patients were subclassified into mild (RAI 3–4), moderate (RAI 5–6) and severe (RAI > 6) groups including 7 patients (46.7%), 7 patients (46.7%), and 1 patient (6.7%) respectively.

When comparing the changes of NLR between no-ACR and ACR group, there was no significant difference; 2.98 ± 1.92 vs. 2.54 ± 1.15 (P = 0.433) at 4 weeks prior to LT, 17.9 ± 8.31 vs. 20.5 ± 13.4 (P = 0.393) at the time of LT, respectively. However, NLR was significantly lower just prior to liver biopsy (5.82 ± 3.42 vs. 8.4 ± 17.2, P = 0.035) in the ACR group compared to the non-ACR group.

The mean value of RI was similar between no-ACR and ACR groups (0.74 ± 0.12 vs. 0.66 ± 0.01, P = 0.518). On analyzing liver function tests, total bilirubin (2.80 ± 2.37 mg/dL vs. 2.32 ± 1.83 mg/dL, P = 0.480), ALP (90.2 ± 48.9 IU/L vs. 86.4 ± 57.2 IU/L, P = 0.308), ALT (58.9 ± 33.3 IU/L vs. 74.1 ± 38.1 IU/L, P = 0.224), AST (152.6 ± 77.9 IU/L vs. 194.5 ± 87.7 IU/L, P = 0.314), and γ-GT (119.9 ± 84.7 IU/L vs. 120.5 ± 95.6 IU/L, P = 0.464) were similar at all 3 occasions between 2 groups. When comparing the changes of peripheral eosinophil counts between no-ACR and ACR groups, it was significantly higher in the ACR group at 4 weeks prior to LT. However, there was no significant difference at LT (1.26 ± 0.79 vs. 1.20 ± 0.23, P = 0.225) and immediately prior to liver biopsy (1.36 ± 0.76 vs. 1.20 ± 1.15, P = 0.118).

Fig. 1 shows the trend of serum neutrophil, lymphocyte, eosinophil, and neutrophil-to-lymphocyte ratio (NLR) according to the postoperative course in the acute cellular rejection (ACR) group. NLR tends to decrease in the 3.5 days before the onset of ACR. LT, liver transplantation.

### Table 2. Relationship between NLR and ACR

| Variable                                      | No ACR (n = 51) | ACR (n = 15) | P-value |
|-----------------------------------------------|-----------------|--------------|---------|
| Rejection activity index score                |                 |              |         |
| 3–4 (mild)                                   | NA              | 7 (46.7)     |         |
| 5–6 (moderate)                               | NA              | 7 (46.7)     |         |
| > 6 (severe)                                 | NA              | 1 (6.7)      |         |
| NLR (%)                                      |                 |              |         |
| 4 wk prior to liver transplantation           | 2.98 ± 1.92     | 2.54 ± 1.15  | 0.433   |
| At liver transplantation                      | 17.9 ± 8.31     | 20.5 ± 13.4  | 0.393   |
| Immediately prior to biopsy                  | 18.4 ± 17.2     | 5.82 ± 3.42  | 0.035   |
| Posttransplant Doppler                        |                 |              |         |
| Resistive index                              | 0.74 ± 0.12     | 0.66 ± 0.01  | 0.518   |
| Liver function test at biopsy                |                 |              |         |
| Total bilirubin (mg/dL)                      | 2.80 ± 2.37     | 2.32 ± 1.83  | 0.480   |
| ALP (IU/L)                                   | 90.2 ± 48.9     | 86.4 ± 57.2  | 0.308   |
| ALT (IU/L)                                   | 58.9 ± 33.3     | 74.1 ± 38.1  | 0.224   |
| AST (IU/L)                                   | 152.6 ± 77.9    | 194.5 ± 87.7 | 0.314   |
| γ-GT (IU/L)                                  | 119.9 ± 84.7    | 120.5 ± 95.6 | 0.464   |
| Peripheral eosinophil count (%)              |                 |              |         |
| 4 wk prior to liver transplantation           | 1.95 ± 0.79     | 3.35 ± 0.51  | 0.001   |
| At liver transplantation                      | 1.26 ± 0.79     | 1.20 ± 0.23  | 0.225   |
| Immediately prior to biopsy                  | 1.36 ± 0.76     | 1.20 ± 1.15  | 0.118   |

Values are presented as number (%) or mean ± standard deviation.

NLR, neutrophil-to-lymphocyte ratio; ACR, acute cellular rejection; NA, not applicable.

Fig. 1. It shows the trend of the percentage of serum neutrophil, lymphocyte, eosinophil, and neutrophil-to-lymphocyte ratio (NLR) according to the postoperative course in the acute cellular rejection (ACR) group. NLR tends to decrease in the 3.5 days before the onset of ACR. LT, liver transplantation.

predicting the occurrence of ACR. In the ROC curve for ACR, the area under the ROC curve of NLR was 81.0%. The optimal cutoff value was 6.49, and the sensitivity and specificity of NLR were 80.4% and 73.3%, respectively.
DISCUSSION

The ACR of the liver graft is a relatively common and well-studied phenomenon, particularly in the early posttransplant period [21]. Allograft rejection against the liver allograft activates the expression of IL-2 and other proinflammatory cytokines that stimulate T cell activation [22]. Consequently, it stimulates T cell proliferation. Therefore, our hypothesis is that the NLR will change due to T cell proliferation in patient with ACR after LDLT.

In this study, the value of NLR was lower in the ACR group than in the non-ACR group around time of ACR. The appropriate cut-off value of NLR to predict ACR development was found to be 6.49, according to the ROC curve. These results show that low levels of NLR may be closely related to the occurrence of ACR. Therefore, NLR has potential as a noninvasive predictor of early ACR who undergoes ABOc LDLT. Therefore, serial monitoring of this ratio will help identify subclinical graft dysfunction before onset of ACR in ABOc LDLT.

There are several possible noninvasive diagnostic tools for the diagnosis of ACR. However, there are few available tests commercially. Screening tests must be easily obtainable, inexpensive, and reproducible for prediction of disease. Elevation of liver enzymes after LT can be a clue to suspect ACR, but it is nonspecific and has a low sensitivity in diagnosing ACR [23]. It also was not well correlated with simultaneous liver biopsy findings [24]. We found no significant difference in liver enzymes between ACR and no-ACR groups, and its clinical significance remains doubtful. Several studies reported that absolute eosinophil count (AEC) and differential count in the peripheral blood have an association with ACR in renal, cardiac, and lung transplantation [25]. In LT, peripheral eosinophilia correlates with graft eosinophilia in ACR [15]. Using a cut-off for AEC of 400/μL and relative eosinophil count of 4%, eosinophilia has excellent specificity (83%–97%) but low sensitivity (28%–38%) for ACR [26]. In this study, no significant difference was found in eosinophil counts between the ACR group and no-ACR group.

Although there are some limitations of noninvasive tools to predict ACR after LDLT, these tools can be used easily in the clinical setting. A cut-off value of 6.49 for NLR showed a sensitivity of 80.4% and a specificity of 73.3% in patients who underwent ABOc LDLT in this study. NLR showed a lower value 3.5 days prior to liver biopsy in patients with ACR.

Protocol biopsies can identify subclinical degrees of ACR and detect the tissue change of the liver graft early [27]. For these reasons, our center performed a protocol liver biopsy on a postoperative day 7. It is helpful to detect the patient without the sign of graft dysfunction. The benefits of treatment of subclinical rejection and the clinical utility of protocol liver biopsy are controversial [28]. In our study, during follow-up, 2 patients (13.3%) developed chronic rejection without proper management because they were not shown any sign of graft dysfunction. Therefore, it is important to detect subclinical rejection using an easy tool. For these reasons, monitoring of noninvasive tools such as NLR can reduce the possibility of liver biopsy related complications and early detection for subclinical ACR.

This study has several limitations. First, we analyzed the patients who underwent ABOc LDLT; ABO-incompatible (ABOi) LDLT and deceased donor LT were excluded from the analysis. In ABOi LDLT, peripheral B cells are eradicated to prevent a posttransplant rebound rise of isoagglutinin by surgical or pharmacological intervention [27]. This depletes antigen presentation of B cells to T cells, cytokine production facilitating T-cell polarization, antibody production, and tertiary lymphoid organ generation [29]. Therefore, these continuous B-cell suppression effects may also affect T-cell proliferation required for ACR. Thus ABOi LDLT patients were excluded from our study. In patients who underwent deceased donor liver transplant, the recipient’s condition, graft status, and immunologic response could be different during peri-transplant period; hence, these patients were excluded from the analysis as well.

Second, the number of enrolled patients was too small; validation with a large number of patients is needed to confirm the result of this study. Third, we had the results of liver biopsy only after LDLT. Even though the values of NLR were similar between the 2 groups 4 weeks prior to LDLT and on the day of LT, pathologic findings itself were not compared at that time.

Despite these limitations of this study, NLR is an easily obtainable and noninvasive tool that can help reveal the
subclinical status of the liver graft. Serial monitoring of these ratios will help to detect of subclinical rejection in ABOc LDLT before liver biopsy. However, we should be confirmed through further multicenter and prospective study in large populations to validate these observations.

ACKNOWLEDGEMENTS

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

ORCID iD
Boram Lee: https://orcid.org/0000-0002-6973-0808
YoungRok Choi: https://orcid.org/0000-0003-2408-7086
Jai Young Cho: https://orcid.org/0000-0002-1376-956X
Yoo-Seok Yoon: https://orcid.org/0000-0001-7621-8557
Ho-Seong Han: https://orcid.org/0000-0001-9659-1260

Author Contribution
Conceptualization: All authors
Formal Analysis: BL, YRC
Investigation: All authors
Methodology: All authors
Project Administration: BL, YRC
Writing – Original Draft: All authors
Writing – Review & Editing: BL, YRC

REFERENCES

1. Maluf DG, Stravitz RT, Cotterell AH, Posner MP, Nakatsuka M, Sterling RK, et al. Adult living donor versus deceased donor liver transplantation: a 6-year single center experience. Am J Transplant 2005;5:149-56.
2. Gruttadauria S, Vasta F, Mandalà L, Cintorino D, Piazza T, Spada M, et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. Transplant Proc 2005;37: 2611-3.
3. Emond JC, Rouch D, Thistlethwaite J, Whittington P, Baker A, Ferrari M, et al. Rejection in liver allograft recipients: clinical characterization and management. Clin transplant 1987;1:143-50.
4. Soin AS, Rasmussen A, Jamieson NV, Watson CJ, Friend PJ, Wight DG, et al. CsA levels in the early posttransplant period: predictive of chronic rejection in liver transplantation? Transplantation 1995;59:1119-23.
5. Neil DA. Hubscher SG. Delay in diagnosis: a factor in the poor outcome of late acute rejection of liver allografts. Transplant Proc 2001;33:1525-6.
6. Thurairajah PH, Carbone M, Bridgestock H, Thomas P, Hebbar S, Gunson BK, et al. Late acute liver allograft rejection: a study of its natural history and graft survival in the current era. Transplantation 2013;95:955-9.
7. Hultcrantz R, Gabriellson N. Patients with persistent elevation of aminotransferases: investigation with ultrasonography, radionuclide imaging and liver biopsy. J Intern Med 1993;233:7-12.
8. Colonna JO 2nd, Brems JJ, Goldstein LJ, Millis JM, Vargas JH, Berquist WE, et al. The importance of percutaneous liver biopsy in the management of the liver transplant recipient. Transplant Proc 1988;20(I Suppl 1):682-4.
9. Kis B, Pamarthi V, Fan CM, Rabkin D, Baum RA. Safety and utility of transjugular liver biopsy in hematopoetic stem cell transplant recipients. J Vasc Interv Radiol 2013;24:85-9.
10. Lebrec D, Goldfarb G, Degott C, Rueff B, Benhamou JP. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology 1982;83:338-40.
11. Van Ha TG. Liver biopsy in liver transplant recipients. Semin Intervent Radiol 2004;21:271-4.
12. Sanada Y, Matsumoto K, Urahashi T, Ihara Y, Wakiya T, Okada N, et al. Protocol liver biopsy is the only examination that can detect mid-term graft fibrosis after pediatric liver transplantation. World J Gastroenterol 2014;20:6638-50.
13. Bathgate AJ, Lee P, Hayes PC, Simpson KJ. Pretransplantation tumor necrosis factor-alpha production predicts acute rejection after liver transplantation. Liver Transpl 2000;6:721-7.
14. Boleslawski E, Conti F, Sanquer S, Podevin P, Chouzenoux S, Batteux F, et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation 2004;77:1815-20.
15. Foster PF, Sankary HN, Hart M, Ashmann M, Williams JW. Blood and graft eosinophilia as predictors of rejection in human liver transplantation. Transplantation 1989;47:72-4.
16. Nagral A, Ben-Ari Z, Dhillon AP, Burroughs AK. Eosinophils in acute cellular rejection in liver allografts. Liver Transpl Surg 1998;4:355-62.
17. De Groen PC, Kephart GM, Gleich GJ, Ludwig J. The eosinophil as an effector cell of the immune response during hepatic allograft rejection. Hepatology 1994;20:654-62.
18. Verhelst XP, Troisi RI, Colle I, Geerts A, van Vlierberghen H. Biomarkers for the diagnosis of acute cellular rejection in liver transplant recipients: a review. Hepatol Res 2013;43:165-78.
19. Kim H, Jung HI, Kwon SH, Bae SH, Kim HC, Baek MJ, et al. Preoperative neutrophil-lymphocyte ratio and CEA is associated with poor prognosis in patients with synchronous colorectal cancer liver metastasis. Ann Surg Treat Res 2019;96:191-200.

20. Ingulli E. Mechanism of cellular rejection in transplantation. Pediatr Nephrol 2010;25:61-74.

21. Taner T. Liver transplantation: rejection and tolerance. Liver Transpl 2017;23(S1): S85-8.

22. Wang D, Matsumoto R, You Y, Che T, Lin XY, Gaffen SL, et al. CD3/CD28 costimulation-induced NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkappaB kinase beta to the immunological synapse through CARMA1. Mol Cell Biol 2004;24:164-71.

23. Kumar S, Mohapatra N, Borle DP, Choudhury A, Sarin S, Gupta E. Non-invasive diagnosis of acute cellular rejection after liver transplantation: current opinion. Transpl Immunol 2018;47:1-9.

24. Henley KS, Lucey MR, Appelman HD, Baliga P, Brown KA, Burtch GD, et al. Biochemical and histopathological correlation in liver transplant: the first 180 days. Hepatology 1992;16:688-93.

25. Shalev O, Rubinger D, Barlatzky Y, Kopolovic J, Drukker A. Eosinophilia associated with acute allograft kidney rejection. Nephron 1982;31:182-3.

26. Hughes VF, Trull AK, Joshi O, Alexander GJ. Monitoring eosinophil activation and liver function after liver transplantation. Transplantation 1998;65:1334-9.

27. Wang YC, Wu TJ, Wu TH, Lee CF, Chou HS, Chan KM, et al. The risk factors to predict acute rejection in liver transplantation. Transplant Proc 2012;44:526-8.

28. Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998;28:638-45.

29. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant 2011;11:i359-67.